- Home
- » Tags
- » Dimethyl fumarate
Top View
- Clinical Policy: Ozanimod (Zeposia)
- Multiple Sclerosis Agents Aubagio® (Teriflunomide) Gilenya® (Fingolimod) Mayzent® (Siponimod) Tecfidera® (Dimethyl Fumarate) Zeposia® (Ozanimod) Effective 01/01/2021
- Role of Disease-Modifying Oral Drugs in Multiple Sclerosis: a Systematic Review with Meta-Analysis
- Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
- Comparative Effectiveness of Teriflunomide and Dimethyl
- Zāļu Patēriņa Statistika Statistics on Medicines Consumption
- Abn Guidance on the Use of Disease-Modifying Therapies in Multiple Sclerosis in Response to the Threat of a Coronavirus Epidemic
- Comparative Effectiveness of Teriflunomide Vs Dimethyl Fumarate in Multiple Sclerosis David-Axel Laplaud, Romain Casey, Laetitia Barbin, Et Al
- Extract from the Clinical Evaluation Report for Diemthyl Fumarate
- Oral Therapies for MS the Advent of Oral Therapies Has Ushered in a New Phase of Disease-Modifying Treatments
- Annual Report 2013
- Hematological Alterations Related to Treatment with Teriflunomide And
- Ozanimod for Relapsing Remitting Multiple Sclerosis
- Tysabri® (Natalizumab) Injection
- Tecfidera (Dimethyl Fumarate)
- Estonian Statistics on Medicines 2012 1/41
- Dimethyl Fumarate > Printer-Friendly PDF
- 11/19/2020 Mayzent (Siponimod) Tablets. It Slow
- USE of DISEASE-MODIFYING THERAPIES in MULTIPLE SCLEROSIS Principles and Current Evidence a Consensus Paper by the Multiple Sclerosis Coalition
- Dimethyl Fumarate Treatment Induces Adaptive and Innate Immune Modulation Independent of Nrf2
- For Patients with Relapsing-Remitting Multiple Sclerosis
- Certolizumab Pegol for Treating Moderate to Severe Plaque Psoriasis
- Dimethyl Fumarate and Its Esters: a Drug with Broad Clinical Utility?
- List of Selected Drugs
- Storm: Dimethyl Fumarate As a Therapeutic Candidate for COVID-19
- Guidelines for ATC Classification and DDD Assignment 2021
- Multiple Sclerosis Therapy – Oral and Subcutaneous
- Skilarence, INN-Dimethyl Fumarate
- Australian Public Assessment Report for Dimethyl Fumarate
- Dimethyl Fumarate Or Any of the Excipients of TECFIDERA Safely and Effectively
- Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4− Myd88 Complex
- Tysabri® (Natalizumab) Injection
- Repurposing Non-Cancer Drugs in Oncology – How Many Drugs Are out There?
- Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate
- ABSTRACT BOOK 21St Congress of the EAHP 16-18 March 2016 Vienna, Austria March 2016
- Dimethyl Fumarate
- Natalizumab Update 2013
- Potential Clinical Implications of the Latest Data on Disease-Modifying Therapies Kirk A
- Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
- Role of Dimethyl Fumarate in the Treatment of Glioblastoma Multiforme
- Relapsing Remitting Multiple Sclerosis: Treatment Update Outline
- (12) United States Patent (10) Patent No.: US 9,452,972 B2 Gangakhedkar Et Al
- Dimethyl Fumarate, Fingolimod, and Teriflunomide Pivotal Studies
- Biologics for the Treatment of Adults with Psoriasis
- Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate
- High Cost Drugs Pathway for Adults with Psoriasis
- Ozanimod 0.23Mg, 0.46Mg and 0.92Mg Hard Capsules (Zeposia®) Celgene Ltd
- Discontinuation of Teriflunomide and Dimethyl Fumarate in a Large Italian Multicentre Population: a 24-Month Real-World Experience
- Tecfidera, Common Name-Dimethyl Fumarate
- GILENYA (Fingolimod) MAVENCLAD (Cladrabine) MAYZENT (Siponimod) PONVORY (Ponesimod) TECFIDERA (Dimethyl Fumarate) VUMERITY (Diroximel Fumarate) ZEPOSIA (Ozanimod)
- MS Progress Notes... a Newsletter for Health Professionals Volume 9, Number 2 Spring 2014
- Tecfidera™ (Dimethyl Fumarate)*, Vumerity™ (Diroximel Fumarate)*, Zeposia (Ozanimod) ®
- 204063Orig1s000
- Cladribine (Mavenclad) Reference Number: CP.PHAR.422 Effective Date: 09.01.19 Last Review Date: 08.20 Line of Business: Commercial, HIM, Medicaid Revision Log